Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Placebo to Basimglurant (Microcrystalline Cellulose Spheres (Vivapur 1000) and hard Gelatin Capsule, Opaque white body/Opaque white cap, Size 1), Basimglurant, Basimglurant
Lacuna Pharma Pty Ltd
Trigeminal neuralgia, Trigeminal neuralgia
1 trial -
Placebo to Match Tinlarebant (LBS-008). Placebo tablets will be prepared similarly with microcrystalline cellulose used in place of the active drug substance. The placebo tablet is identical in size, appearance, and other physical properties to the LBS-008 tablet., LBS-008
ELITE PHARMACEUTICALS INC /NV/
Geographic Atrophy
1 trial -
Placebo to Remibrutinib (LOU064) 0 mg matching 00 mg film-coated tablet, TRIAMCINOLONE , Placebo to Remibrutinib (LOU064) 0 mg matching 00 mg film-coated tablet, LOU064, CLINDAMYCIN , LOU064, -
Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
1 trial -
Placebo to Remibrutinib (LOU064) 00 mg film-coated tablet, LOU064
Novartis Pharmaceuticals
Generalized Myasthenia Gravis
1 trial -
Placebo to Remibrutinib (LOU064) XX mg film-coated tablet, LOU064, LOU064, Placebo to Remibrutinib (LOU064) XX mg film-coated tablet
Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
1 trial -
Placebo to Remibrutinib (LOU064) film-coated tablets, LOU064
Novartis Pharmaceuticals
Secondary progressive multiple sclerosis
1 trial -
Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device, TQJ230
Novartis Pharmaceuticals
Cardiovascular Disease
1 trial -
Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, VAY736, -
Novartis Pharmaceuticals
SjΓΆgrenβs Syndrome
1 trial -
Placebo to match Linaprazan glurate 50mg, Placebo to match Lansoprazole 30 mg, Linaprazan glurate, LANSOPRAZOLE
Lacuna Pharma Pty Ltd
Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)
1 trial -
Placebo to match Paltusotine tablets 20 mg, Paltusotine tablets
Lacuna Pharma Pty Ltd
Acromegaly
1 trial -
Placebo to match paltusotine tablets 20 mg, Paltusotine tablets
Lacuna Pharma Pty Ltd
Acromegaly
1 trial -
Placebo to remibrutinib (LOU064) 25 mg film-coated tablet, -, LOU064, -
Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
1 trial -
Placebo will be provided in size and appearance identical to those containing milsaperidone and will be administered orally., Milsaperidone, Milsaperidone, Milsaperidone
Vanda Pharmaceuticals Netherlands B.V.
Major Depressive Disorder
1 trial -
Placebo, Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC)
Lacuna Pharma Pty Ltd
Atherosclerotic Cardiovascular Disease
1 trial -
Placebo, Paltusotine 40 mg tablets, Paltusotine 40 mg tablets
Lacuna Pharma Pty Ltd
Carcinoid syndrome
1 trial -
Placebo, XPF-010
Xenon Pharmaceuticals
Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)
1 trial -
Placebo, capsule, ZYTIGA 500 mg film-coated tablets, Prednison acis 5 mg, Tabletten, Fuzuloparib
Lacuna Pharma Pty Ltd
Metastatic Castration-Resistant Prostate Cancer
1 trial -
Placebo, oral solution, Maralixibat chloride
Lacuna Pharma Pty Ltd
Cholestatic Pruritus
1 trial -
Plozasiran
Arrowhead Pharmaceuticals Ireland Limited
Severe Hypertriglyceridemia
1 trial -
Plozasiran
Arrowhead Pharmaceuticals Ireland Limited
Familial Chylomicronemia Syndrome
1 trial -
Plozasiran
Arrowhead Pharmaceuticals Ireland Limited
Familial Chylomicronemia
1 trial -
Plozasiran Injection
Arrowhead Pharmaceuticals Ireland Limited
Severe Hypertriglyceridemia
2 trials -
Plozasiran Injection
Arrowhead Pharmaceuticals Ireland Limited
Hypertriglyceridemia
2 trials -
Plozasiran Injection Placebo, ARO-APOC3 PFS
Arrowhead Pharmaceuticals Ireland Limited
Severe hypertriglyceridemia (SHTG)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources